2型糖尿病的最新药物治疗研究进展  

Research Progress on the Latest Drug Treatment of Type 2 Diabetes Melli⁃tus

作　　者：葛文娜[1] GE Wenna(Department of Pharmacy,Linyi Hospital of Traditional Chinese Medicine,Linyi 276002,Shandong,China)

机构地区：[1]临沂市中医医院药学部,山东临沂276002

出　　处：《糖尿病新世界》2024年第24期191-193,198,共4页Diabetes New World

摘　　要：2型糖尿病(type 2 diabetes mellitus,T2DM)是全球范围内频发的慢性疾病,其疾病负担较重,应积极采取有效的治疗。除了传统口服降糖药(涵盖双胍类、磺脲类、α-糖苷酶抑制剂和非磺脲类胰岛素促泌剂)和胰岛素类药物外,还有诸多学者对T2DM新型药物研发及疗效分析进行相关报道,例如钠-葡萄糖协同转运蛋白2抑制剂、二肽基肽酶4抑制剂、胰高糖素样肽-1受体激动剂等已成为T2DM的二线治疗选择,显示出显著的降糖效果和心血管保护作用。本研究将对T2DM药物治疗及新兴药物研究进展作一综述。Type 2 diabetes mellitus(T2DM)is a chronic disease with frequent occurrence worldwide,and its disease burden is heavy,so effective treatment should be taken actively.In addition to traditional oral hypoglycemic drugs(in⁃cluding metformin,sulfonylurea,alpha glucosidase inhibitors,and non sulfonylurea insulin secretagogues)and insulin drugs,many scholars have reported on the development and efficacy analysis of new drugs for T2DM,such as sodiumdependent glucose transporters 2 inhibitor,dipeptidyl peptidase 4 inhibitor,and glucagon-like peptide-1 receptor ago⁃nists,which have become second-line treatment options for T2DM,showing significant hypoglycemic and cardiovascu⁃lar protective effects.This study will provide a review of the drug therapy for T2DM and the research progress of emerging drugs.

关 键 词：2型糖尿病 钠-葡萄糖协同转运蛋白2抑制剂 二肽基肽酶4抑制剂 胰高糖素样肽-1受体激动剂 药物 

分 类 号：R587[医药卫生—内分泌]